NVIV Stock Price, InVivo Therapeutics Holdings Quote, Chart

Market Summary

USD0.370.00

Market Closed

0.00%

NVIV Stock Price

View Fullscreen

NVIV RSI Chart

NVIV Valuation

Market Cap

1.1M

Price/Earnings (Trailing)

-0.12

Price/Free Cashflow

-0.11

NVIV Price/Sales (Trailing)

NVIV Profitability

Return on Equity

-104.59%

Return on Assets

-97.32%

Free Cashflow Yield

-885.37%

NVIV Fundamentals

NVIV Earnings

Earnings (TTM)

-9.3M

Earnings Growth (Yr)

2.11%

Earnings Growth (Qtr)

-39.24%

Breaking Down NVIV Revenue

Last 7 days

60.9%

Last 30 days

48%

Last 90 days

-52.6%

Trailing 12 Months

-63%

How does NVIV drawdown profile look like?

NVIV Financial Health

Current Ratio

14.3

NVIV Investor Care

Shares Dilution (1Y)

62.17%

Diluted EPS (TTM)

-3.28

Tracking the Latest Insider Buys and Sells of InVivo Therapeutics Holdings Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 06, 2023	foose brice	bought	-75,460	0.460122	-164,000	-
Feb 06, 2023	foose brice	sold	-75,460	0.460122	-164,000	-
Feb 05, 2023	foose brice	bought	-47,570	0.286566	-166,000	-
Feb 05, 2023	foose brice	sold	-47,570	0.286566	-166,000	-
Dec 21, 2021	toselli richard m.	sold (taxes)	-8.64	0.54	-16.00	see remarks
Jun 21, 2021	toselli richard m.	sold (taxes)	-15.54	0.74	-21.00	see remarks
Dec 21, 2020	toselli richard m.	sold (taxes)	-9.6	0.6	-16.00	see remarks
Jun 19, 2020	toselli richard m.	sold (taxes)	-25.5	1.7	-15.00	see remarks
Mar 10, 2020	christopher richard	bought	-	-	3,636	cfo and treasurer
Mar 10, 2020	merrifield c ann	bought	-	-	3,636	-

Which funds bought or sold NVIV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	VIMA LLC	added	100	3.00	4.00	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	new	-	5,223	5,223	-%
May 15, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-6,128	-	-%
May 15, 2024	BARCLAYS PLC	new	-	-	-	-%
May 15, 2024	MORGAN STANLEY	sold off	-100	-197	-	-%
May 14, 2024	Colonial Trust Advisors	sold off	-100	-1.00	-	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	sold off	-100	-13,634	-	-%
May 13, 2024	UBS Group AG	sold off	-100	-1.00	-	-%
May 10, 2024	VANGUARD GROUP INC	sold off	-100	-22,804	-	-%
May 10, 2024	BlackRock Inc.	sold off	-100	-25,341	-	-%

Are Funds Buying or Selling NVIV?

Are funds buying NVIV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NVIV

No. of Funds

Unveiling InVivo Therapeutics Holdings Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	4.99%	163,100	SC 13G/A
Feb 13, 2024	lind global fund ii lp	3.9%	125,520	SC 13G/A
Feb 06, 2024	foose brice	-	0	SC 13G/A
Apr 25, 2023	foose brice	11.5%	330,000	SC 13G
Feb 14, 2023	armistice capital, llc	9.99%	244,999	SC 13G
Feb 13, 2023	lind global macro fund lp	6.3%	128,321	SC 13G/A
Feb 11, 2022	intracoastal capital, llc	2.5%	864,933	SC 13G/A
Feb 09, 2022	lind global macro fund lp	8.4%	3,138,000	SC 13G/A
Feb 16, 2021	cvi investments, inc.	-	1,018,701	SC 13G/A
Feb 09, 2021	l1 capital global opportunities master fund, ltd.	4.8%	1,061,250	SC 13G/A

Recent SEC filings of InVivo Therapeutics Holdings Corp

View All Filings

Date Filed	Form Type	Document
Mar 21, 2024	25-NSE	25-NSE
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to InVivo Therapeutics Holdings Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

InVivo Therapeutics Holdings Corp News

Latest updates

InVivo Therapeutics Holdings Corp Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	-28.1%	9,584	13,334	15,652	18,822	13,355	16,071	18,541	21,770	23,573	25,814	27,683	21,910	10,512	12,742	12,434	9,325	11,144	13,608	16,971	18,377	21,476
Current Assets	-23.8%	9,525	12,504	14,606	17,601	11,559	13,577	15,994	19,142	21,391	23,555	25,518	19,656	8,184	10,339	9,972	6,783	8,526	10,909	14,325	17,125	20,348
Cash Equivalents	-20.0%	8,581	10,720	13,149	16,351	10,747	13,178	15,326	19,181	21,251	23,174	24,877	19,603	8,011	9,941	9,315	6,716	8,250	10,012	13,317	16,774	19,801
Net PPE	-75.7%	9.00	37.00	152	227	229	183	140	127	77.00	68.00	76.00	85.00	83.00	82.00	66.00	73.00	70.00	79.00	89.00	100	112
Liabilities	-62.1%	666	1,757	2,176	3,076	3,259	3,257	3,025	3,655	2,629	2,504	2,159	2,724	2,705	2,712	2,874	3,742	3,287	3,140	3,427	2,266	2,994
Current Liabilities	-51.3%	666	1,368	1,650	2,420	2,501	2,407	2,077	2,612	2,010	1,798	1,475	1,972	1,867	1,792	1,871	2,663	2,127	1,906	2,089	2,205	2,938
Shareholder's Equity	-23.0%	8,918	11,577	13,476	15,746	10,096	12,814	15,516	18,115	20,944	23,310	25,524	19,186	7,807	10,030	9,560	5,583	7,857	10,468	13,544	16,111	18,482
Retained Earnings	-1.1%	-255,585	-252,888	-250,951	-248,619	-246,258	-243,503	-240,784	-238,129	-235,217	-232,766	-230,457	-228,234	-226,042	-223,763	-221,574	-219,160	-215,788	-213,109	-209,965	-207,330	-204,805
Additional Paid-In Capital	0.0%	264,500	264,462	264,424	264,362	256,351	256,314	256,297	256,241	256,158	256,073	255,978	247,417	233,847	233,791	231,132	224,741	223,644	223,576	223,508	223,440	223,286
Shares Outstanding	0%	3,105	3,105	3,105	2,429	1,391	1,383	1,370	1,371	1,371	1,370	1,179	945	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	5,632	-	-	-	25,348	-	-	-	7,672	-	-	-	6,883	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	6.9%	-2,282	-2,451	-3,204	-2,191	-2,370	-2,092	-3,829	-2,011	-1,905	-1,703	-3,235	-1,922	-1,925	-1,965	-3,722	-1,889	-1,762	-3,305	-3,358	-2,987	-2,553
Share Based Compensation	0%	38.00	38.00	62.00	49.00	37.00	17.00	56.00	83.00	85.00	95.00	52.00	44.00	56.00	45.00	70.00	65.00	68.00	68.00	67.00	77.00	85.00
Cashflow From Investing	95.5%	43.00	22.00	2.00	-17.00	-61.00	-56.00	-26.00	-59.00	-	-	-	-13.00	-5.00	-	-	-	-	-	-	-	-
Cashflow From Financing	-	-	-	-	-	-	-	-	-	-	-	8,509	13,527	-	2,614	6,321	367	-	-	-99.00	-40.00	-68.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NVIV Income Statement

2023-09-30

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 703	$ 1,168	$ 2,799	$ 3,948
General and administrative	2,125	1,632	4,602	4,247
Total operating expenses	2,828	2,800	7,401	8,195
Operating loss	(2,828)	(2,800)	(7,401)	(8,195)
Other income:
Interest income (expense), net	130	45	434	57
Other income	1		1	9
Interest and other income, net	131	45	435	66
Net loss	$ (2,697)	$ (2,755)	$ (6,966)	$ (8,129)
Net loss per share, basic	$ (0.87)	$ (1.98)	$ (2.33)	$ (5.88)
Net loss per share, diluted			$ (2.33)	$ (5.88)
Weighted average number of common shares outstanding, basic (In Shares)	3,105,956	1,391,481	2,983,916	1,382,118
Weighted average number of common shares outstanding, diluted (In Shares)	3,105,956	1,391,481	2,983,916	1,382,118

NVIV Balance Sheet

2023-09-30

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 8,581	$ 16,351
Prepaid expenses	623	97
Other current assets	321	1,153
Total current assets	9,525	17,601
Property, equipment and leasehold improvements, net	9	227
Restricted cash - non-current	50	150
Operating lease right-of-use assets		844
Total assets	9,584	18,822
Current liabilities:
Accounts payable	123	617
Operating lease liabilities		396
Accrued expenses	543	1,407
Total current liabilities	666	2,420
Other liabilities		103
Operating lease liabilities - non-current		553
Total liabilities	666	3,076
Commitments and contingencies (Note 5)
Stockholders' equity:
Preferred stock, $0.00001 par value, authorized 1,000,000 at September 30, 2023 and December 31, 2022. No Preferred Stock issued and outstanding at September 30, 2023 and December 31, 2022
Common stock, $0.00001 par value, authorized 250,000,000 at September 30, 2023 and December 31, 2022. 3,105,446 and 2,429,446 shares issued and outstanding	3	3
Additional paid-in capital	264,500	264,362
Accumulated deficit	(255,585)	(248,619)
Total stockholders' equity	8,918	15,746
Total liabilities and stockholders' equity	$ 9,584	$ 18,822

About InVivo Therapeutics Holdings Corp

InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Richard M. Toselli
WEBSITE	invivotherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	6

InVivo Therapeutics Holdings Corp Frequently Asked Questions

What is the ticker symbol for InVivo Therapeutics Holdings Corp? What does NVIV stand for in stocks?

NVIV is the stock ticker symbol of InVivo Therapeutics Holdings Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of InVivo Therapeutics Holdings Corp (NVIV)?

As of Tue Apr 16 2024, market cap of InVivo Therapeutics Holdings Corp is 1.15 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NVIV stock?

You can check NVIV's fair value in chart for subscribers.

What is the fair value of NVIV stock?

You can check NVIV's fair value in chart for subscribers. The fair value of InVivo Therapeutics Holdings Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of InVivo Therapeutics Holdings Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NVIV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is InVivo Therapeutics Holdings Corp a good stock to buy?

The fair value guage provides a quick view whether NVIV is over valued or under valued. Whether InVivo Therapeutics Holdings Corp is cheap or expensive depends on the assumptions which impact InVivo Therapeutics Holdings Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NVIV.

What is 5 year return on InVivo Therapeutics Holdings Corp's stock?

In the past 10 years, InVivo Therapeutics Holdings Corp has provided -0.718 (multiply by 100 for percentage) rate of return.